{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T05:39:53Z","timestamp":1770961193969,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"33","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.vaccine.2012.05.052","type":"journal-article","created":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T17:02:26Z","timestamp":1338570146000},"page":"4945-4952","source":"Crossref","is-referenced-by-count":17,"title":["Febrile events including convulsions following the administration of four brands of 2010 and 2011 inactivated seasonal influenza vaccine in NZ infants and children: The importance of routine active safety surveillance"],"prefix":"10.1016","volume":"30","author":[{"given":"Helen","family":"Petousis-Harris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracey","family":"Poole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikki","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"34","key":"10.1016\/j.vaccine.2012.05.052_bib0005","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1016\/j.vaccine.2011.05.040","article-title":"Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysis","volume":"29","author":"Beyer","year":"2011","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.vaccine.2012.05.052_bib0010","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1016\/j.vaccine.2009.01.125","article-title":"Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring","volume":"27","author":"Vellozzi","year":"2009","journal-title":"Vaccine"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2012.05.052_bib0015","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1542\/peds.2004-1519","article-title":"Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990\u20132003","volume":"115","author":"McMahon","year":"2005","journal-title":"Pediatrics"},{"issue":"November (20)","key":"10.1016\/j.vaccine.2012.05.052_bib0020","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1001\/jama.292.20.2478","article-title":"Guillain\u2013Barre syndrome following influenza vaccination","volume":"292","author":"Haber","year":"2004","journal-title":"JAMA"},{"issue":"October (16)","key":"10.1016\/j.vaccine.2012.05.052_bib0025","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1001\/jama.296.16.1990","article-title":"Safety of trivalent inactivated influenza vaccine in children 6\u201323 months old","volume":"296","author":"Hambidge","year":"2006","journal-title":"JAMA"},{"issue":"November (11)","key":"10.1016\/j.vaccine.2012.05.052_bib0030","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/archpedi.158.11.1031","article-title":"Safety of the trivalent inactivated influenza vaccine among children: a population-based study","volume":"158","author":"France","year":"2004","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"January (2)","key":"10.1016\/j.vaccine.2012.05.052_bib0035","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/aje\/kwp345","article-title":"Near real-time surveillance for influenza vaccine safety: proof-of-concept in the vaccine safety datalink project","volume":"171","author":"Greene","year":"2010","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2012.05.052_bib0210","unstructured":"Department of Health and Human Services. Center for Biologics Evaluation and Research, editor. Guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines. United States Food and Drug Administration; 2007."},{"key":"10.1016\/j.vaccine.2012.05.052_bib0045","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004879.pub3","article-title":"Vaccines for preventing influenza in healthy children","volume":"2","author":"Jefferson","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2012.05.052_bib0050","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1586\/erv.11.53","article-title":"Pediatric influenza immunization","volume":"10","author":"Petrovsky","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2012.05.052_bib0055","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1016\/j.vaccine.2011.02.012","article-title":"Fever following administration of two inactivated influenza vaccines \u2013 a survey of parents of New Zealand infants and children 5 years of age and under","volume":"29","author":"Petousis-Harris","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.05.052_bib0060","series-title":"Investigation into febrile reactions in young children following 2010 seasonal trivalent influenza vaccination","year":"2010"},{"issue":"May","key":"10.1016\/j.vaccine.2012.05.052_bib0065","article-title":"Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine","author":"Armstrong","year":"2011","journal-title":"BMJ Open 2011"},{"key":"10.1016\/j.vaccine.2012.05.052_bib0070","unstructured":"CSL Biotherapies (New Zealand) Ltd. Fluvax Product Datasheet. 2011 [cited 2012 16 May]. Available from: http:\/\/www.medsafe.govt.nz\/profs\/Datasheet\/SearchResult.asp."},{"key":"10.1016\/j.vaccine.2012.05.052_bib0075","unstructured":"Sanofi pasteur. Vaxigrip Product Datasheet. 2011 [cited 2012 16 May]. Available from: http:\/\/www.medsafe.govt.nz\/profs\/Datasheet\/SearchResult.asp."},{"key":"10.1016\/j.vaccine.2012.05.052_bib0080","unstructured":"GlaxoSmithKline NZ Ltd. Fluarix Product Datasheet. 2011 [cited 2012 16 May]. Available from: http:\/\/www.medsafe.govt.nz\/profs\/Datasheet\/SearchResult.asp."},{"issue":"5\u20136","key":"10.1016\/j.vaccine.2012.05.052_bib0085","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.vaccine.2003.09.007","article-title":"Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation","volume":"22","author":"Michael Marcy","year":"2004","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2012.05.052_bib0090","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1203\/00006450-196907000-00005","article-title":"Studies on convulsive disorders in young children: incidence of Febrile and Nonfebrile convulsions by age and other factors","volume":"3","author":"Van den Berg","year":"1969","journal-title":"Pediatr Res"},{"key":"10.1016\/j.vaccine.2012.05.052_bib0095","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/j.1528-1157.1994.tb05932.x","article-title":"Incidence of Convulsive Disorders in Children","volume":"35","author":"Hauser","year":"1994","journal-title":"Epilepsia"},{"issue":"October","key":"10.1016\/j.vaccine.2012.05.052_bib0100","article-title":"Relationship between the population incidence of febrile convulsions in young children in Sydney Australia and seasonal epidemics of influenza and respiratory syncytial virus, 2003\u20132010: a time series analysis","volume":"11","author":"Polkinghorne","year":"2011","journal-title":"BMC Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2012.05.052_bib0105","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jinf.2012.01.014","article-title":"Influenza-associated illness is an important contributor to febrile convulsions in Danish children","volume":"64","author":"Harder","year":"2012","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2012.05.052_bib0110","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1750-2659.2009.00108.x","article-title":"Safety and immunogenicity of an inactivated thiomersal-free influenza vaccine in infants and children","volume":"3","author":"Nolan","year":"2009","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2012.05.052_bib0115","unstructured":"CSL Limited Alfuria Package Insert. Available at: http:\/\/wwwfdagov\/downloads\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm220730pdf [accessed 14.02.10]."},{"issue":"October (16)","key":"10.1016\/j.vaccine.2012.05.052_bib0120","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1001\/jama.296.16.1990","article-title":"Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old","volume":"296","author":"Hambidge","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2012.05.052_bib0125","series-title":"Seasonal flu vaccines: no evidence of an increased risk of febrile convulsions in children","year":"2010"},{"issue":"2","key":"10.1016\/j.vaccine.2012.05.052_bib0130","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/INF.0b013e31823d5303","article-title":"Influenza Vaccine Safety in Children less than 5 years old: the 2010 and 2011 experience in Australia","volume":"31","author":"Wood","year":"2012","journal-title":"Pediatr Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2012.05.052_bib0135","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/j.vaccine.2012.01.027","article-title":"Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010\u20132011","volume":"30","author":"Tse","year":"2012","journal-title":"Vaccine"},{"issue":"December (21)","key":"10.1016\/j.vaccine.2012.05.052_bib0140","first-page":"2353","article-title":"Update: Recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding use of CSL Seasonal Influenza Vaccine (Afluria) in the United States during 2010\u201311","volume":"304","author":"ACIP.","year":"2010","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.vaccine.2012.05.052_bib0145","doi-asserted-by":"crossref","first-page":"596","DOI":"10.4049\/jimmunol.96.4.596","article-title":"Influenza virus subunit vaccines: immunogenicity and lack of toxicity for rabbits of ether- and detergent-disrupted virus","volume":"96","author":"Webster","year":"1966","journal-title":"J Immunol (Baltimore, Md: 1950)"},{"issue":"3\u20135","key":"10.1016\/j.vaccine.2012.05.052_bib0150","first-page":"639","article-title":"Desoxycholate-split influenza vaccines","volume":"41","author":"Warbuton","year":"1969","journal-title":"Bull World Health Organ"},{"issue":"October (8)","key":"10.1016\/j.vaccine.2012.05.052_bib0155","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1086\/378274","article-title":"Randomized, double-blind, placebo-controlled trial to assess the rate of recurrence of oculorespiratory syndrome following influenza vaccination among persons previously affected","volume":"37","author":"Skowronski","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2012.05.052_bib0160","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0264-410X(98)90040-8","article-title":"Responses to one or two doses of a deoxycholate subunit influenza vaccine in a primed population","volume":"2","author":"Tannock","year":"1984","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2012.05.052_bib0165","doi-asserted-by":"crossref","first-page":"318","DOI":"10.5694\/mja11.10941","article-title":"Adverse events associated with 2010 CSL and other inactivated influenza vaccines","volume":"195","author":"Kelly","year":"2011","journal-title":"Med J Aust"},{"key":"10.1016\/j.vaccine.2012.05.052_bib0170","unstructured":"Food and Drug Administration (US). Inspections, compliance, enforcement, and criminal investigations. Warning letter to Commonwealth Serum Laboratories (CSL), Ltd. 6\/15\/11. 2011."},{"key":"10.1016\/j.vaccine.2012.05.052_bib0175","series-title":"Scientific investigations of trivalent influenza vaccine-induced adverse events in the paediatric population: role of innate immunity. Potential use of biomarkers of inflammation and of early immunological events to assess vaccine safety","author":"Maraskovsky","year":"2012"},{"issue":"32","key":"10.1016\/j.vaccine.2012.05.052_bib0180","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1016\/j.vaccine.2011.05.054","article-title":"Trivalent influenza vaccine and febrile adverse events in Australia, 2010: clinical features and potential mechanisms","volume":"29","author":"Blyth","year":"2011","journal-title":"Vaccine"},{"issue":"20","key":"10.1016\/j.vaccine.2012.05.052_bib0185","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1016\/j.vaccine.2005.12.069","article-title":"Geographic and ethnic variations of long-term efficacy and immunogenicity of hepatitis B vaccination in Hualien, a HBV hyperendemic area","volume":"24","author":"Wang","year":"2006","journal-title":"Vaccine"},{"issue":"5-6","key":"10.1016\/j.vaccine.2012.05.052_bib0190","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S0264-410X(01)00387-5","article-title":"Anthrax vaccine: short-term safety experience in humans","volume":"20","author":"Pittman","year":"2001","journal-title":"Vaccine"},{"issue":"September (3 (Pt 2))","key":"10.1016\/j.vaccine.2012.05.052_bib0195","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1542\/peds.96.3.584","article-title":"Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines","volume":"96","author":"Christy","year":"1995","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2012.05.052_bib0200","unstructured":"Petousis-Harris H. Factors associated with vaccine reactogenicity in school aged children and young adults following administration of two protein-based vaccines. PhD thesis Auckland: University of Auckland; 2012."},{"key":"10.1016\/j.vaccine.2012.05.052_bib0205","series-title":"Influenza surveillance in New Zealand 2010","author":"Institute of Environmental and Science Research Ltd","year":"2011"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12007785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12007785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T01:55:41Z","timestamp":1687485341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X12007785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":41,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0264410X12007785"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.05.052","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}